Medicxi Ventures Management (Jersey) LTD Vaxcyte, Inc. Transaction History

Medicxi Ventures Management (Jersey) LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 18, 2023	SELL	$46.0 - $53.1 $12.2 Million - $14.1 Million	-265,542 Reduced 20.19%	1,049,893 $53.5 Million
Q2 2023 Jul 19, 2023	SELL	$34.66 - $54.07 $4.92 Million - $7.67 Million	-141,865 Reduced 9.73%	1,315,435 $65.7 Million
Q4 2022 Jan 31, 2023	SELL	$20.58 - $47.95 $8.85 Million - $20.6 Million	-430,178 Reduced 22.79%	1,457,300 $69.9 Million
Q2 2020 Aug 07, 2020	BUY	$26.15 - $35.45 $49.4 Million - $66.9 Million	1,887,478 New	1,887,478 $59.7 Million

354

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.42B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Medicxi Ventures Management (Jersey) LTD, based on Form 13F filings with the SEC.

Stay updated on Medicxi Ventures Management (Jersey) LTD with notifications on news.